Brendon Stiles   Associate Professor of Cardiothoracic Surgery

  • +1 212 746 0848

Dr. Stiles has a long standing interest in basic science research.  Since joining the faculty at Weill Cornell, Dr. Stiles has received research grants from the Thoracic Surgery Foundation for Education and Research, the STARR cancer consortium, the Qatar National Research Fund, and the Lung Cancer Research Foundation.  In 2014, he received an inaugural Cardiothoracic Surgical Investigator Grant from the American Association for Thoracic Surgery, Graham Foundation, supporting innovative translational research for Cardiothoracic Surgeons.  Dr. Stiles, along with Dr. Timothy McGraw and Dr. Vivek Mittal in the Neuberger Berman Lung Cancer Research Center, recently received the prestigious 2015 Metastasis Research Grant from Free to Breathe.  The current focus of Dr. Stiles' work is the role of the protein ART1 in lung cancer development and progression.  

Dr. Stiles is Chair of the Board of the Lung Cancer Research Foundation and is a grant reviewer for that organization, for the DOD Lung Cancer Research Program (for which he has also chaired several panels), and for the Thoracic Surgery Foundation.  

Dr. Stiles is also active in clinical research. He has written numerous manuscripts and book chapters.  Particular interests include the detection and management of small pulmonary nodules, lung cancer staging, perioperative management of lung cancer patients, and prognostic factors in esophageal cancer.  Dr. Stiles has presented his work on the national stage, at such meetings as the American Association for Thoracic Surgery, the Society of Thoracic Surgeons, and others. Peer-reviewed publications may be reviewed on the accompanying web page.


Sort by

Selected publications


research overview

  • At Weill Cornell, as part of the Meyer Cancer Center, our Lung Cancer Research Lab is at the forefront of team science. We understand that meaningful advances in translational science can only be made when outstanding clinicians partner with leading basic scientists.  I work closely with researchers from multiple disciplines to better understand lung cancer, in particular how proteins and cells in the tumor microenvironment affect tumor growth and suppression. These studies will help us to understand how different patients respond to immunotherapy or to cytotoxic chemotherapy and may potentially identify new therapeutic targets.

    We are also working hard to develop biomarkers for lung cancer, in order to better classify lung nodules detected in our Lung Cancer Screening Program. We utilize novel platforms for biomarker discovery using materials biobanked from consenting patients at the time of surgery. We anticipate that such biomarkers will also have prognostic implications and may be used to guide therapeutic decisions.

    We strongly believe that in order to cure patients with lung cancer or other malignancies, we have to study cancers taken directly from our patients.  This ability to take patient-derived materials directly to pathology and then to the laboratory, allows us to move science from the bedside to the bench and then hopefully back again.  Team science makes it happen.

Funding awarded

  • Targeting ART1, a novel immune checkpoint, for the treatment of lung cancer  awarded by United States Department of Defense Principal Investigator 2019 - 2021



Primary Email